Clinical Trials Browser

Lymphoma, Follicular × Dosage Forms × 1 year × Clear all

NCT04345718 2025-12-09

EXHITENTRE

Phase 2/3 Completed

Lymphoma, Follicular, Opioid-Related Disorders, Substance-Related Disorders